 |
Robert J. Rosenthal is Magellan's founding president and chief executive officer. A proven executive, Dr. Rosenthal has 20 years of experience building value for customers, shareholders, and employees in companies serving the biomedical research and diagnostics industries. Most recently, Dr. Rosenthal was president and CEO of Boston Life Sciences, an R&D development-stage biopharmaceutical company. Previously, he was president of PerkinElmer's Instruments division, where he managed the acquisition and integration of the Analytical Instruments group from PE Corporation. As president and CEO of Thermo Optek, Dr. Rosenthal built a market-leading instrument company, which went public in 1996. Prior to Thermo Optek, Dr. Rosenthal served as president of Nicolet Instrument Corporation, a subsidiary of Thermo Instruments, which supplies analytical tools for research and development to several industries, including biotechnology. In addition to the Magellan and subsidiary boards, Dr. Rosenthal serves on several others, including the boards of Matritech (AMEX:MZT), a developer of proteomics-based diagnostic products for the early detection of cancer, Safeguard Scientifics, Inc. (NYSE:SFE), a holding company that builds value in growth-stage technology and life sciences businesses, and the University of Maryland Department of Chemistry and Biochemistry Board of Advisors. He is also a member of the University of Maryland, College of Chemical and Life Sciences Board of Visitors.
Dr. Rosenthal holds a BS in chemistry from the University of Maryland, an MS in chemistry from State University of New York (Buffalo), and a PhD in physical chemistry from Emory University. He spent a year in Germany completing a post-doctoral fellowship and as a guest scientist of the Alexander von Humboldt Foundation. This was followed by an additional post-doctoral fellowship at UCLA. Dr. Rosenthal also holds an AEA Executive MBA from Stanford University. |
